Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years

An important free-access report on the PARTNER 3 trial that discusses the TAVI-first policy in patietns with Society of Thoracic Surgeons Predicted Risk of Mortality risk less than 4% ( mean of 1.9%).
The calls from the surgeons to re examine the optimum strategy may be somewhat vindicated by the 26% higher 5-year mortality of the Sapiens group of products compared to open aortic valve strategies.It follows that the end-users must be informed of this nuance in raw data. This mortality corresponds to the landmark analysis of re-hospitalisation/
The debate is predicted to continue throughout the next few years, and data and guidelines will be forthcoming on this most important research question. The OPERA-TAVI publications are soon to shed more light from the standpoint of a rival product,